# Phase IIb Study of MP4OX in Traumatic Hemorrhagic Shock Patients

> **NCT01262196** · PHASE2 · COMPLETED · sponsor: **Sangart** · enrollment: 348 (actual)

## Conditions studied

- Shock, Hemorrhagic
- Shock, Traumatic
- Acidosis, Lactic

## Interventions

- **DRUG:** MP4OX
- **DRUG:** Saline

## Key facts

- **NCT ID:** NCT01262196
- **Lead sponsor:** Sangart
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-05
- **Primary completion:** 2012-10
- **Final completion:** 2012-11
- **Target enrollment:** 348 (ACTUAL)
- **Last updated:** 2013-08-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01262196

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01262196, "Phase IIb Study of MP4OX in Traumatic Hemorrhagic Shock Patients". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01262196. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*